ArticleIntestinal research2014

A high risk group in the modified national institutes of health consensus criteria for the gastrointestinal stromal tumor: a clear indication of the adjuvant imatinib.

Dong Kyung ChangPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.